M. Matles

Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase

S. Leavitt, T. Appleby, M. Fenaux, 2012, Antimicrobial Agents and Chemotherapy.

Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.

M. Desai, G. Cheng, E. Mogalian, 2014, Journal of medicinal chemistry.

Characterization of a KDM5 Small Molecule Inhibitor with Antiviral Activity against Hepatitis B Virus

Gregg A. Czerwieniec, Helen Yu, T. Appleby, 2022, bioRxiv.

Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection.

S. Leavitt, T. Appleby, M. Fenaux, 2014, Journal of medicinal chemistry.

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

Gregg A. Czerwieniec, Helen Yu, T. Appleby, 2022, bioRxiv.

Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors.

W. Zhong, G. Cheng, Xubin Zheng, 2011, ACS medicinal chemistry letters.

In vivo pharmacodynamics of GS-5801, a liver targeted prodrug of a lysine demethylase 5 inhibitor with antiviral activity against hepatitis B virus

W. Delaney, B. Feierbach, C. Snyder, 2017 .

Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection.

T. Appleby, M. Fenaux, Xiaowu Chen, 2014, Journal of medicinal chemistry.